Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Go back to Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema| Dominion Resources (NYSE: D) | Delayed: 68.04 -0.37 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.41 | 52 Week High | $78.97 | |||
| Open | $68.80 | 52 Week Low | $64.54 | |||
| Day High | $69.19 | P/E | 56.70 | |||
| Day Low | $67.87 | EPS | $1.20 | |||
| Volume | 9,226,239 | |||||
| Ryder System (NYSE: R) | Delayed: 265.06 +1.69 (0.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $263.37 | 52 Week High | $80.15 | |||
| Open | $263.74 | 52 Week Low | $45.12 | |||
| Day High | $267.58 | P/E | 57.25 | |||
| Day Low | $260.83 | EPS | $4.63 | |||
| Volume | 355,680 | |||||
